IMS Launch Aims for Gold Standard

Healthcare and pharma information giant IMS Health has announced a comprehensive global program – 'New Models, New Metrics' – to provide the industry's 'next generation of market measurement services'. The program's first launch is 'MIDAS Market Segmentation™'.

MIDAS aims to provide a new global standard for measuring and analyzing the generics market segment including patent protection status. The tool categorizes generics products into consistent types and reclassifies the overall pharmaceutical market, assigning a specific intellectual property protection status to each product. Together with IMS's existing analytical and consulting capabilities, the launch aims to improve clients' forecasting, scenario modeling, competitive benchmarking and portfolio planning activities.

The offering, developed in close collaboration with clients and industry associations, is now available in the US, Canada, 11 EU countries and South Africa, with rollout to an additional 13 European countries and Japan in 2007.

Executive VP Gilles Pajot comments: 'The landscape of the pharmaceutical marketplace has changed dramatically in recent years, driven by specialty products, new channels, payer pressures, emerging markets and, especially, generics growth. The implications of these changes for the healthcare and pharmaceutical industries are profound.'

Future offerings under New Models, New Metrics will address emerging markets, parallel trade, specialty channels, disease and treatment patterns, and other evolving market dynamics.

IMS had revenues of $1.8 billion in 2005 and is online at www.imshealth.com .

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.

• IMS Health Inc
• All news